Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

What it really takes to be a great place to work

There’s no one-size-fits-all model, but it can be done at virtually any organization.

Fortune

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

StockNews.com

Broader Market Settles Higher on Improved Soft-Landing Prospects

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.38%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. Stocks on Thursday settled mixed, with the Dow Jones...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Mixed as Higher Bond Yields Weigh on Tech Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.84%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.77%. Stocks this morning are mixed, with the Dow Jones...

Barchart

3 Defensive Dividend Stocks to Protect Your Portfolio

Dividend-paying stocks are having a tough year, but there are still some top-rated income picks worth buying at current levels. Here's a look at three dividend stocks that can actually help defend your portfolio from market volatility.

Barchart

Can Pfizer (PFE) and AbbVie (ABBV) Cure Your Portfolio's Ailments?

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Amid this, let’s analyze the fundamentals of AbbVie (ABBV) and Pfizer (PFE) to determine whether these stocks are worth buying now.

StockNews.com

Top 3 Pharma Stocks to Boost Your Portfolio

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Building Wealth with Spinoffs: How Adding These Gems Can Transform Your Portfolio

Spinoffs are value creating investment opportunities. You should be looking at them

Barchart

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

Salon

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

StockNews.com

AbbVie’s Underperformance, Deere’s Catch-Up Potential, And Pioneer’s Earnings Awaited

AbbVie's underperformance, Jim Lebenthal sees Deere as a catch-up trade, and analysts await Pioneer's earnings report.

Zenger

3 High-Paying Unusually Active Put Options to Sell for Extra Cash This Weekend

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

Barchart

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

Cheaper competition for Humira is hitting the market, but savings will depend on your insurance

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

3 Dependable Dividend Stocks to Consider in the Second Half Of 2023

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.

Kiplinger

Best Retirement Stocks for Income Investors in the Golden Years

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.

Barchart

AbbVie’s Call Action Suggests It Might Just Be a Buy

Barchart.com’s Unusual Options Activity on Wednesday had 18 AbbVie call options in the Top 100. Not everyone believes it’s an excellent time to buy ABBV stock. Yesterday’s options market says otherwise.

Fortune

How Fortune 500 companies are supporting employees amid financial instability

Financial wellness benefits have become popular as employers focus on retention.

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Reskilling and financial well-being top HR’s talent strategy list amid economic downturn

Fortune 500 HR execs share how they’re recession-proofing their talent strategy. Hint: Financial wellness benefits and reskilling.

Chicago Tribune

Federal government to penalize AbbVie over the price of its blockbuster drug Humira

North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the federal government said Wednesday.

StockNews.com

3 Income Stocks to Buy Now if You're Starving for Cash

The Fed will likely keep raising interest rates to bring inflation down to its desired level. This is expected to keep the stock market and the economy under pressure this year. Amid the uncertainty, investors looking for passive income could add fundamentally strong dividend-paying stocks AbbVie (ABBV), Valero Energy (VLO),…

WEKU

AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

The Guardian - UK

Ignore the ‘superpower’ boasts – UK pharma looks superchallenged

NHS crisis, withdrawal of tax credits and exit from EU blamed for fall in UK share of R&D market

StockNews.com

The #1 Pharma Stock to Buy in January 2023

While the stock market and the economy have been subdued by progressive interest-rate increases, AbbVie Inc. (ABBV) has not only reported a robust third quarter but also demonstrated its confidence in its long-term prospects by raising its quarterly dividend. Read on….

StockNews.com

4 Warren Buffett Stocks to Buy and Never Sell

Legendary investor Warren Buffett’s holding company Berkshire Hathaway has outperformed the broader market over the past year. His investment portfolio has been a guide for several long-term investors for decades. Amid a highly uncertain market and economic backdrop, Warren Buffett holdings Procter & Gamble (PG), AbbVie (ABBV), Biogen (BIIB), and…

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.